ALXO241220C2000
- 0.10
- 0.000.00%
ALX Oncology Newsroom
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination With Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Highlights Promising Trial Results
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Maintains Target Price $3
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
Positive Outlook for ALX Oncology: Buy Rating Backed by Promising Clinical Data and Strong Financials
ALX Oncology GAAP EPS of -$0.58
Express News | ALX Oncology Holdings - Board Appointed Shelly Pinto as Co's Interim CFO
Express News | ALX Oncology Holdings - on Nov 5, Peter Garcia, CFO of Co Informed of His Resignation From His Position Effective Nov 8
ALX Oncology | 8-K: ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology | 10-Q: Q3 2024 Earnings Report
Express News | ALX Oncology Q3 Net Income USD -30.707 Million
Express News | ALX Oncology Q3 Basic EPS USD -0.58
Press Release: ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology Announces Results From Phase 1b/2 Trial of Evorpacept in Combination With Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Express News | ALX Oncology Announces Results From Phase 1B/2 Trial of Evorpacept in Combination With Zanidatamab Will Be Presented at the San Antonio Breast Cancer Symposium (Sabcs) 2024